[Long-lasting LDL-C lowering: silence at last].

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Genetics

Background:

• Proprotein convertase subtilisin/kexin type 9 (PCSK9) accelerates LDL-receptor degradation.
• Elevated LDL-cholesterol (LDL-C) is a major cardiovascular risk factor.
• Statins are a primary treatment, but some patients are intolerant.

Purpose of the Study:

• To evaluate the efficacy of inclisiran in reducing LDL-C levels.
• To assess inclisiran's safety and effectiveness in diverse patient populations.

Main Methods:

• Inclisiran is a synthetic small interfering RNA (siRNA) targeting PCSK9 mRNA.
• Administered subcutaneously at baseline, 3 months, and then every 6 months.
• Clinical trials in patients with high cardiovascular risk, familial hypercholesterolemia, and statin intolerance.

Main Results:

• Consistent reduction of LDL-C by approximately 50% was observed.
• Effective in patients with high/very-high cardiovascular risk and familial hypercholesterolemia.
• Demonstrated efficacy in patients intolerant to statins.

Conclusions:

• Inclisiran offers a new therapeutic option for managing hypercholesterolemia.
• Its RNA silencing mechanism provides sustained LDL-C reduction.
• Further data on cardiovascular outcomes and adolescent safety are anticipated.